It has been learned that the application document submitted by CSPC Innovation Pharmaceutical Co., Ltd. (referred to as CSPC Innovation, 300765.SZ) for its Hong Kong initial public offering, filed on December 10, 2025, has lapsed as of June 10, 2026, after being active for six months. At the time of the application, CITIC Securities acted as its sole sponsor.
According to the prospectus, the company is focused on the research and development, production, and commercialization of biopharmaceuticals, functional ingredients, and health foods. The company has continued to deepen its presence in the broader health sector. In 2024, it gained control of Jushi Bio, expanding its core business into the biopharmaceutical industry, marking a key step in its strategic corporate transformation.
The company concentrates on developing innovative therapies with differentiated targets through multiple technological pathways. It has accumulated substantial technical expertise in the fields of antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines. Its strategic focus is on disease areas with significant unmet clinical needs and high growth potential, including oncology, autoimmune diseases, and infectious diseases.
In the second half of 2024, the company commenced the commercialization of two antibody drugs: the Class 1 innovative drug Enshuxing® (an anti-PD-1 monoclonal antibody) and Enyitan®, China's first omalizumab biosimilar. In the mRNA vaccine segment, its products Du'entai® (which, according to Frost & Sullivan data, is the first domestically developed COVID-19 mRNA vaccine in China) and Du'entai 2® (a bivalent COVID-19 mRNA vaccine targeting mainstream variants such as XBB.1.5) were authorized for emergency use in China in 2023.
As of the latest practicable date (December 1, 2025), the company had 15 drug candidates in clinical or advanced development stages, including nine ADC candidates and one mRNA vaccine candidate.
Comments